Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients

ISSN
2072-1439
Date Issued
2020-03
Author(s)
von Eiff, Damian
Bozorgmehr, Farastuk
Chung, Inn
Bernhardt, Denise
Liersch, Stephan
Muley, Thomas
Kobinger, Sonja
Thomas, Michael
Christopoulos, Petros
Steins, Martin
DOI
10.21037/jtd.2019.12.74
Abstract
Etoposide-/platinum-based chemotherapy is the standard first-line treatment for extensive-disease small cell lung cancer (SCLC), but responses are short-lived and subsequent options limited. Here, we present our experience with paclitaxel in advanced treatment lines.